In 2018,National Science Review interviewed Prof.David R.Liu of the Broad Institute,who pioneered CRISPR-based genome-editing technologies[1].As soon as this interview was posted on China's social media,a father of a Duchenne muscular dys-trophy(DMD)patient contacted us,hoping Liu's innovation could save his son.The DMD patients usually lose the ability to stand and walk by the age of 12,and many do not survive beyond 20 years old.Similarly to rare-disease families through-out the world,rare-disease patients in China are desperately in search of possible therapy.Since 20 15,attention on rare diseases has been mounting in China,with emerging new policies and programs.Compared with their counterparts in the USA and Europe,rare-disease patients in China are facing many more challenges in receiving diagnosis and treatment.On 18-19 De-cember 2021,the 2021 China Conference on Rare Diseases was held online.Hundreds of physicians,researchers,policy-makers,patients and medical-industry representatives gathered to dis-cuss multiple aspects of rare diseases in China.

Weijie Zhao

国家科学评论（英文版）

[1]Weijie Zhao-.China's campaign against rare diseases)[J].国家科学评论（英文版）,2022(05):191-193

desperately

China,campaign,against,rare,diseases,National,Review,interviewed,Prof,David,Liu,Broad,Institute,who,pioneered,CRISPR,genome,editing,technologies,soon,this,was,posted,social,media,father,Duchenne,muscular,dys,trophy,DMD,contacted,hoping,innovation,could,save,son,patients,usually,lose,ability,stand,walk,by,age,many,do,not,survive,beyond,years,old,Similarly,families,through,out,world,possible,therapy,Since,attention,has,been,mounting,emerging,new,policies,programs,Compared,their,counterparts,USA,Europe,facing,more,challenges,receiving,diagnosis,treatment,On,De,cember,Conference,Rare,Diseases,held,online,Hundreds,physicians,researchers,policy,makers,medical,industry,representatives,gathered,cuss,multiple,aspects

0.698424